KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $634.0 million.

  • Teva Pharmaceutical Industries' Operating Expenses rose 1548.27% to $634.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.3 billion, marking a year-over-year increase of 653.08%. This contributed to the annual value of $2.3 billion for FY2025, which is 653.08% up from last year.
  • According to the latest figures from Q4 2025, Teva Pharmaceutical Industries' Operating Expenses is $634.0 million, which was up 1548.27% from $573.0 million recorded in Q3 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Operating Expenses peaked at $634.0 million during Q4 2025, and registered a low of $458.0 million during Q3 2022.
  • Moreover, its 5-year median value for Operating Expenses was $534.0 million (2023), whereas its average is $533.1 million.
  • In the last 5 years, Teva Pharmaceutical Industries' Operating Expenses plummeted by 1596.77% in 2021 and then soared by 1548.27% in 2025.
  • Quarter analysis of 5 years shows Teva Pharmaceutical Industries' Operating Expenses stood at $521.0 million in 2021, then decreased by 4.41% to $498.0 million in 2022, then increased by 4.22% to $519.0 million in 2023, then rose by 5.78% to $549.0 million in 2024, then grew by 15.48% to $634.0 million in 2025.
  • Its Operating Expenses stands at $634.0 million for Q4 2025, versus $573.0 million for Q3 2025 and $549.0 million for Q2 2025.